[New era for MS treatment. Severe setback when it comes to enthusiasm--highly effective agent caused serious adverse effects].
Olsson
Tomas
T
Institutionen för klinisk neurovetenskap, Karolinska Universitetssjukhuset, Solna. tomas.olsson@cmm.ki.se
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab